Community Research and Development Information Service - CORDIS


Final Report - PROMARK (Genetic prostate cancer variants as biomarkers of disease progression)

Project ID: 202059
Funded under: FP7-HEALTH


The greatest unmet clinical need in prostate cancer is the development of predictive methods or markers that can help distinguish between early stage tumours that will remain confined to the prostate and those which will progress to an invasive, aggressive form of the disease.

The 'PROMARK' project, which was funded by the European Community (EC), aimed to test if inherited genetic variants can serve as biomarkers for disease prognosis or treatment selection and to perform analysis of predictive variants in order to shed light on the patho-physiology of disease progression.

This document is an attachment to PROMARK's final report and lists the patents that resulted as part of the undertaken research activities and their level of confidentiality.

Download application/zip (183276)

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top